Spyre Therapeutics (SYRE) said late Monday that it has commenced an underwritten public offering of its shares.
Investors can also buy pre-funded warrants in lieu, the clinical-stage biotechnology firm said. It expects to grant underwriters a 30-day option to buy additional shares.